Abstract:Background and Aim. Sphingosine kinase 1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in the pathogenesis and progression of human cancer. It has been demonstrated to be upregulated in various types of human malignancies. However, the prognostic value of SPHK1 remains unclear. Therefore, we performed this meta-analysis to assess its predictive value in the prognosis of cancer patients. Methods. PubMed, Web of Science, Embase, CNKI, and Wanfang databases were thoroughly searched for eligible studies, in which the relationship between SPHK1 expression and cancer prognosis was evaluated. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to estimate the impact of SPHK1 expression on cancer patients’ survival. Odds ratios (ORs) and 95% CIs were combined to assess the association between SPHK1 expression and clinicopathological characteristics of cancer patients. The certainty of evidence was evaluated by Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria. Results. Thirty studies comprising 32 cohorts with 5965 patients were included in this meta-analysis. The outcomes indicated that elevated SPHK1 expression was associated with worse overall survival (OS) ( HR = 1.71 , 95% CI: 1.45-2.01, P < 0.001 ) and disease-free survival (DFS) ( HR = 1.34 , 95% CI: 1.13-1.59, P = 0.001 ). What is more, SPHK1 overexpression was significantly correlated with certain phenotypes of tumor aggressiveness, such as clinical stage ( OR = 2.07 , 95% CI: 1.39-3.09, P < 0.001 ), tumor invasion ( OR = 2.16 , 95% CI: 1.47-3.18, P < 0.001 ), lymph node metastasis ( OR = 2.04 , 95% CI: 1.71-2.44, P < 0.001 ), and distant metastasis ( OR = 3.16 , 95% CI: 2.44-4.09, P < 0.001 ). The quality of the evidence for both OS and DFS was low. Conclusions. Increased SPHK1 expression is related to poor prognosis in human cancers and may serve as a promising prognostic marker and therapeutic target for malignant patients. However, conclusions need to be treated with caution because of lack of high quality of evidence.

Sphingosine 1-Phosphate: A Potential Molecular Target for Ovarian Cancer Therapy?

Sphingosine Kinase 1/Sphingosine-1-phosphate (S1P)/S1P Receptor Axis is Involved in Ovarian Cancer Angiogenesis

Advances of Sphingosine-1-phosphate in Angiogenesis

Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer

The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy

Sphingosine Kinase 1 Contributes to the Metastatic Potential of Epithelial Ovarian Cancer to the Adipocyte-Rich Niche

Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target

Activation of SphK1 by adipocytes mediates epithelial ovarian cancer cell proliferation

Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming

S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway

Keep a Little Fire Burning—The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity

Sugt1 Regulates the Progression of Ovarian Cancer Through the Akt/Pi3k/Mtor Signaling Pathway

Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy

Inhibition of Sphingosine Kinase 2 Down-Regulates ERK/c-Myc Pathway and Reduces Cell Proliferation in Human Epithelial Ovarian Cancer

Sphingosine-1-Phosphate in the Tumor Microenvironment: A Signaling Hub Regulating Cancer Hallmarks

Role of Sphingosine-1-Phosphate Signaling Pathway in Pancreatic Diseases

Increased Sphingosine Kinase 1 Expression is Associated with Poor Prognosis in Human Solid Tumors: A Meta-Analysis

Study on Effect of S1P/S1PR on Angiogenesis in SKOV3 Ovarian Cancer Cells

Recent advances in the role of sphingosine 1‐phosphate in cancer

SPP1 is a prognostic related biomarker and correlated with tumor-infiltrating immune cells in ovarian cancer

Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target